CINECA IRIS Institutional Research Information System

D'AMBROSIO, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.594
EU - Europa 1.517
AS - Asia 926
SA - Sud America 72
OC - Oceania 32
AF - Africa 26
Continente sconosciuto - Info sul continente non disponibili 4
Totale 5.171
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.491
IT - Italia 590
CN - Cina 487
DE - Germania 179
IE - Irlanda 139
JP - Giappone 113
GB - Regno Unito 102
FR - Francia 85
SE - Svezia 83
CA - Canada 68
IN - India 61
ES - Italia 56
VN - Vietnam 54
PL - Polonia 50
TR - Turchia 44
BR - Brasile 34
NL - Olanda 31
AU - Australia 29
FI - Finlandia 28
MX - Messico 28
KR - Corea 27
TW - Taiwan 26
SG - Singapore 25
UA - Ucraina 23
HK - Hong Kong 21
NO - Norvegia 18
AT - Austria 17
RU - Federazione Russa 17
BE - Belgio 16
IL - Israele 16
TH - Thailandia 15
CH - Svizzera 14
CO - Colombia 13
AR - Argentina 12
HR - Croazia 11
PT - Portogallo 11
GR - Grecia 10
RO - Romania 10
MA - Marocco 7
SA - Arabia Saudita 7
EG - Egitto 6
HU - Ungheria 6
IR - Iran 5
PE - Perù 5
BY - Bielorussia 4
DK - Danimarca 4
ID - Indonesia 4
LT - Lituania 4
MY - Malesia 4
PH - Filippine 4
VE - Venezuela 4
ZA - Sudafrica 4
CR - Costa Rica 3
KE - Kenya 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
OM - Oman 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CL - Cile 2
CZ - Repubblica Ceca 2
EU - Europa 2
NG - Nigeria 2
PK - Pakistan 2
RS - Serbia 2
SN - Senegal 2
TN - Tunisia 2
UZ - Uzbekistan 2
EC - Ecuador 1
JO - Giordania 1
LU - Lussemburgo 1
PR - Porto Rico 1
PY - Paraguay 1
QA - Qatar 1
SI - Slovenia 1
Totale 5.171
Salva come PNG Salva come JPEG
Città #
Chandler 273
Fairfield 212
Ashburn 156
Dublin 139
Redwood City 131
Beijing 126
Houston 119
Woodbridge 109
Wilmington 89
Ann Arbor 86
Seattle 85
Torino 84
Shanghai 74
Cambridge 73
Turin 60
Pisa 54
Nyköping 52
Guangzhou 37
Milan 36
Warsaw 33
Dong Ket 32
Jacksonville 32
Medford 32
Munich 32
Dearborn 31
Rome 31
Princeton 27
Villeurbanne 26
Mcallen 24
Montréal 22
Hangzhou 20
San Diego 20
Tokyo 20
Nanjing 18
Taipei 17
Boston 15
New York 15
Zhengzhou 15
Wuhan 14
Chengdu 12
Chicago 12
Fremont 12
Barcelona 11
Bari 11
Dresden 11
Madrid 11
Washington 11
Indianapolis 10
Ottawa 10
Ankara 9
Hebei 9
Los Angeles 9
Paris 9
Upper Marlboro 9
Amsterdam 8
Birmingham 8
Buenos Aires 8
Carrara 8
Changsha 8
Columbus 8
Genoa 8
Heidelberg 8
Istanbul 8
Mumbai 8
Phoenix 8
Seoul 8
Singapore 8
Stavanger 8
Berlin 7
Fuzhou 7
Hamburg 7
Hefei 7
London 7
Sydney 7
Xian 7
Baltimore 6
Billings 6
Bogotá 6
Central 6
Cincinnati 6
Florence 6
Graz 6
Hong Kong 6
Leeds 6
Oslo 6
Padova 6
Pittsburgh 6
San Francisco 6
St Petersburg 6
Sterling Heights 6
Tel Aviv 6
Toronto 6
Tübingen 6
Vienna 6
Ahmedabad 5
Bangalore 5
Bologna 5
Brussels 5
Changchun 5
Cuneo 5
Totale 2.932
Salva come PNG Salva come JPEG
Nome #
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.041
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 459
Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients 451
Anticoagulation for central venous catheters in patients with cancer. 328
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 262
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 192
Alpha-fetoprotein elevation in NUT midline carcinoma: a case report 174
Preventing Venous Thromboembolism in Patients with Cancer 168
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 166
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 162
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 141
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 133
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 131
Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin's lymphoma: a case report and review of the literature. 119
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 117
Next generation immune-checkpoints for cancer therapy 103
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 96
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 94
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. 92
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 91
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 78
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 77
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 60
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 57
High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series 49
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 48
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 48
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 44
Delving into PARP inhibition from bench to bedside and back 42
Eribulin-based treatment in patients affected by sarcomas: a case series 29
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 28
How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience 28
First and further-line multidisciplinary treatment of retroperitoneal sarcomas 27
What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? 25
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group 24
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas 17
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study 16
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group 15
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients 15
Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions 14
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST) 11
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 8
Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma 8
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas 6
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 6
Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals 4
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial 4
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 2
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study 1
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group 1
MST1 mediates doxorubicin-induced cardiomyopathy by SIRT3 downregulation 1
Totale 5.313
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.811
article - articoli 0
book - libri 0
conference - conferenze 303
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.114
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019234 0 0 0 0 0 0 0 0 0 61 112 61
2019/2020936 48 55 42 101 61 102 82 84 88 97 98 78
2020/2021869 58 57 80 89 76 73 61 68 64 88 55 100
2021/2022725 54 45 52 60 55 44 49 50 42 56 125 93
2022/20231.047 67 66 42 104 88 223 95 96 120 42 65 39
2023/2024594 63 125 60 66 56 78 48 54 8 36 0 0
Totale 5.313